Meta-analysis of the efficacy and safety of P2Y inhibitor monotherapy after short course of dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention
Article (Faculty180)
Elzanaty, Ah M; Nazir, Salik; Awad, Mohammed T; Elsheikh, Eman; Ahuja, Kee R; Donato, Anthony; Eltahawy, Eh A
description
Guidelines recommend dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) placement for ≥12 months in acute coronary syndrome or 6 months in stable coronary artery disease. However, with the advent of newer-generation stents, the optimal duration of DAPT to balance bleeding and thrombotic risks has been debated.